{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Immunotherapies for Pediatric B-Cell Acute Lymphoblastic Leukemia Patients
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
To provide information on the management of children with B-cell acute lymphoblastic leukemia (B-ALL) using immunotherapies.Learning Objectives
After completing this continuing education activity you will be able to:
- Describe current therapies for pediatric B-ALL patients.
- Identify several therapies being investigated in ongoing clinical studies with pediatric B-ALL patients.
Disclosures
The author has disclosed that the U.S. Food and Drug Administration has not approved the use of inotuzumab for pediatric patients with relapsed refractory B-ALL as noted in this article. Please consult the product?s labeling for approved information. The author, faculty, staff, and planners, including spouses/partners (if any), in any position to control the content of this activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity.
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- KY-BON 1.0 CH
- GA - BON 1.0 CH
Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT0519
Published: May 2019
Expires: 12/31/2026
Sources:
Oncology Times
Required Passing Score: 7/10 (70%)